Development of an Enantioselective and Biomarker-Informed Translational Population Pharmacokinetic/Pharmacodynamic Model for Etodolac

Cyclooxygenase-2 (COX-2) isoform has a critical role in the development of pain. Inhibition of COX-2 in vitro serves as a biomarker for nonsteroidal anti-inflammatory drugs (NSAIDs). The NSAID concentrations yielding 80% COX-2 inhibition (IC80) correlate with therapeutic doses to achieve analgesia across multiple COX-2 inhibitors. However, there are no time-course models relating COX-2 inhibition with decreased pain. This study aimed to characterize the relationship between NSAID concentrations, in vitro COX-2 inhibition, and acute pain decrease in humans over time by a translational approach using clinical pharmacokinetic and literature reported in vitro and clinical pharmacodynamic data. In a two-way cross-over study, eight healthy volunteers received 300 and 400 mg racemic etodolac, a preferential COX-2 inhibitor. R- and S-etodolac were determined by LC-MS/MS and simultaneously modeled. Literature in vitro IC50 data for COX-2 inhibition by S-etodolac were used to fit adjusted pain score profiles from dental patients receiving etodolac. External model qualification was performed using published ibuprofen data. Etodolac absorption was highly variable due to gastric transit kinetics and low aqueous solubility. The disposition parameters differed substantially between enantiomers with a total clearance of 2.21 L/h for R-etodolac and 26.8 L/h for S-etodolac. Volume of distribution at steady-state was 14.6 L for R-etodolac and 45.8 L for S-etodolac. Inhibition of COX-2 by 78.1% caused a half-maximal pain decrease. The time-course of pain decrease following ibuprofen was successfully predicted via the developed translational model. This proposed enantioselective pharmacodynamic-informed approach presents the first quantitative time-course model for COX-2 induced pain inhibition in patients.

[1]  C. Pace-Asciak,et al.  RESOLUTION OF ETODOLAC AND ANTIINFLAMMATORY AND PROSTAGLANDIN SYNTHETASE INHIBITING PROPERTIES OF THE ENANTIOMERS , 1984 .

[2]  S. Davis,et al.  Alimentary tract andpancreas Transit ofpharmaceutical dosage forms through the , 1986 .

[3]  C. Demerson,et al.  Etodolac (1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid): a potent antiinflammatory drug. Conformation and absolute configuration of its active enantiomer. , 1986, Journal of medicinal chemistry.

[4]  M. Cayen,et al.  Disposition and biotransformation of 14C-etodolac in man. , 1986, Xenobiotica; the fate of foreign compounds in biological systems.

[5]  F. Jamali,et al.  Application of a stereospecific high-performance liquid chromatography assay to a pharmacokinetic study of etodolac enantiomers in humans. , 1988, Journal of pharmaceutical sciences.

[6]  F. Jamali,et al.  The pharmacokinetics of etodolac enantiomers in the rat. Lack of pharmacokinetic interaction between enantiomers. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[7]  F. Jamali,et al.  Stereoselective Disposition of Etodolac Enantiomers in Synovial Fluid , 1991, Journal of clinical pharmacology.

[8]  F. Jamali,et al.  The Stereoselective Pharmacokinetics of Etodolac in Young and Elderly Subjects, and After Cholecystectomy , 1992, Journal of clinical pharmacology.

[9]  F. Jamali,et al.  Etodolac Clinical Pharmacokinetics , 1994, Clinical pharmacokinetics.

[10]  S. Iacobelli,et al.  Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. , 1994, The Journal of pharmacology and experimental therapeutics.

[11]  K. Mccarroll,et al.  Comparative study of ibuprofen lysine and acetaminophen in patients with postoperative dental pain. , 1995, Clinical therapeutics.

[12]  K. Glaser,et al.  Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. , 1995, European journal of pharmacology.

[13]  F. Lapicque,et al.  Albumin binding sites for etodolac enantiomers. , 1996, Chirality.

[14]  R. Brugger,et al.  Effects of ibuprofen enantiomers and its coenzyme A thioesters on human prostaglandin endoperoxide synthases , 1997, British journal of pharmacology.

[15]  R. Jones,et al.  Etodolac: An overview of a selective COX-2 inhibitor , 1999, InflammoPharmacology.

[16]  J. Vane,et al.  Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[17]  S. Cooper,et al.  Conventional and extended-release etodolac for postsurgical dental pain. , 1999, Clinical therapeutics.

[18]  J. Boni,et al.  Pharmacokinetic and Pharmacodynamic Action of Etodolac in Patients after Oral Surgery , 1999, Journal of clinical pharmacology.

[19]  Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate. , 2001, British journal of clinical pharmacology.

[20]  R Gordon,et al.  Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. , 2001, The Journal of pharmacology and experimental therapeutics.

[21]  Y. Ohno,et al.  Stereoselective glucuronidation and hydroxylation of etodolac by UGT1A9 and CYP2C9 in man , 2004, Xenobiotica; the fate of foreign compounds in biological systems.

[22]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[23]  G. Sarosi,et al.  Risks of clinically significant upper gastrointestinal events with etodolac and naproxen: a historical cohort analysis. , 2004, Gastroenterology.

[24]  C. Brideau,et al.  A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors , 1996, Inflammation Research.

[25]  N. Holford,et al.  Models for describing absorption rate and estimating extent of bioavailability: Application to cefetamet pivoxil , 1992, Journal of Pharmacokinetics and Biopharmaceutics.

[26]  M. Danhof,et al.  Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. , 2005, Rheumatology.

[27]  Varun Garg,et al.  Comparison of four basic models of indirect pharmacodynamic responses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[28]  Meindert Danhof,et al.  Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. , 2007, Annual review of pharmacology and toxicology.

[29]  K. Hamada,et al.  Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo. , 2008, Urology.

[30]  Robert J. Bauer,et al.  A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples , 2007, The AAPS Journal.

[31]  I. Bartal,et al.  Perioperative Use of β-blockers and COX-2 Inhibitors May Improve Immune Competence and Reduce the Risk of Tumor Metastasis , 2008, Annals of Surgical Oncology.

[32]  R. Borojevic,et al.  Racemic Etodolac is cytotoxic and cytostatic for B-cell precursor acute lymphoblastic leukemia cells. , 2009, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[33]  U. Holzgrabe,et al.  New Semiphysiological Absorption Model To Assess the Pharmacodynamic Profile of Cefuroxime Axetil Using Nonparametric and Parametric Population Pharmacokinetics , 2009, Antimicrobial Agents and Chemotherapy.

[34]  M. El-Nabarawi,et al.  Polymeric Surfactant Based Etodolac Chewable Tablets: Formulation and In Vivo Evaluation , 2010, AAPS PharmSciTech.

[35]  H. Tokuda,et al.  Chemopreventive activities of etodolac and oxyphenbutazone against mouse skin carcinogenesis. , 2010, Bioorganic & medicinal chemistry letters.

[36]  H. Mönnikes,et al.  Magnetic marker monitoring: high resolution real-time tracking of oral solid dosage forms in the gastrointestinal tract. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[37]  Dion R. Brocks,et al.  Multiple Peaking Phenomena in Pharmacokinetic Disposition , 2010, Clinical pharmacokinetics.

[38]  T. Post,et al.  Disease Progression Analysis: Towards Mechanism-Based Models , 2011 .

[39]  K. Hasegawa,et al.  Effects of a selective COX-2 inhibitor in patients with uterine endometrial cancers , 2011, Archives of Gynecology and Obstetrics.

[40]  Jurgen B. Bulitta,et al.  Performance and Robustness of the Monte Carlo Importance Sampling Algorithm Using Parallelized S-ADAPT for Basic and Complex Mechanistic Models , 2011, The AAPS Journal.

[41]  N. Inoue,et al.  The enantiomers of etodolac, a racemic anti-inflammatory agent, play different roles in efficacy and gastrointestinal safety. , 2011, Biological & pharmaceutical bulletin.

[42]  Jurgen Bernd Bulitta,et al.  Development of a New Pre- and Post-Processing Tool (SADAPT-TRAN) for Nonlinear Mixed-Effects Modeling in S-ADAPT , 2011, The AAPS Journal.

[43]  D. M. van der Heijde,et al.  Safety of Nonsteroidal Antiinflammatory Drugs and/or Paracetamol in People Receiving Methotrexate for Inflammatory Arthritis: A Cochrane Systematic Review , 2012, The Journal of Rheumatology. Supplement.

[44]  I. Hewala,et al.  Enantioselective HPLC-DAD method for the determination of etodolac enantiomers in tablets, human plasma and application to comparative pharmacokinetic study of both enantiomers after a single oral dose to twelve healthy volunteers. , 2014, Talanta.

[45]  K. Brune,et al.  New insights into the use of currently available non-steroidal anti-inflammatory drugs , 2015, Journal of pain research.

[46]  R. Altman,et al.  PharmGKB summary: ibuprofen pathways , 2015, Pharmacogenetics and genomics.

[47]  E. Donadi,et al.  Enantioselective analysis of etodolac in human plasma by LC-MS/MS: Application to clinical pharmacokinetics. , 2016, Journal of pharmaceutical and biomedical analysis.

[48]  Lena Jaeger,et al.  Analytical Profiles Of Drug Substances And Excipients , 2016 .